| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/AJH.23390 |
| P698 | PubMed publication ID | 23440663 |
| P2093 | author name string | S Vincent Rajkumar | |
| P2860 | cites work | A long-term study of prognosis in monoclonal gammopathy of undetermined significance. | Q55035699 |
| Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study | Q56995088 | ||
| Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide | Q57903992 | ||
| Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial | Q57904015 | ||
| Redefining myeloma | Q58030074 | ||
| Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma | Q58050813 | ||
| Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma | Q58415969 | ||
| Identification of a primary target of thalidomide teratogenicity | Q24302178 | ||
| Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma | Q24605861 | ||
| Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma | Q24647620 | ||
| Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study | Q24653006 | ||
| Multiple myeloma | Q24655964 | ||
| Cancer statistics, 2012 | Q27860574 | ||
| Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group | Q28207984 | ||
| International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma | Q28243968 | ||
| Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial | Q28252396 | ||
| Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial | Q30433139 | ||
| Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression | Q33376149 | ||
| Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma | Q33377526 | ||
| Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma | Q33386052 | ||
| Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma | Q33386405 | ||
| Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma | Q33389111 | ||
| Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). | Q33391803 | ||
| Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study | Q33394981 | ||
| A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma | Q33401596 | ||
| A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma | Q33402536 | ||
| Solitary plasmacytoma of bone and extramedullary plasmacytoma | Q33811600 | ||
| Antitumor activity of thalidomide in refractory multiple myeloma | Q33880642 | ||
| Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance | Q33887470 | ||
| Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials | Q33931651 | ||
| Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study | Q33942495 | ||
| A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival | Q33957196 | ||
| Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study | Q33997173 | ||
| POEMS syndrome | Q34006873 | ||
| An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma | Q34008600 | ||
| Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy | Q34122646 | ||
| POEMS syndrome: definitions and long-term outcome | Q34161383 | ||
| High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma | Q34195428 | ||
| Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. | Q34210005 | ||
| International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. | Q34241661 | ||
| Lenalidomide after stem-cell transplantation for multiple myeloma | Q34273726 | ||
| Incidence of multiple myeloma in Olmsted County, Minnesota: Trend over 6 decades | Q34358438 | ||
| Multiple myeloma. | Q34362643 | ||
| International staging system for multiple myeloma | Q34408882 | ||
| Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study | Q43048164 | ||
| Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma | Q43071494 | ||
| Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial. | Q43081275 | ||
| Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial | Q43109172 | ||
| High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. | Q43573096 | ||
| Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance? | Q43824187 | ||
| Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis | Q44190664 | ||
| Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. | Q44492438 | ||
| Clinical course of patients with relapsed multiple myeloma | Q44544763 | ||
| Single versus double autologous stem-cell transplantation for multiple myeloma. | Q44706045 | ||
| Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. | Q46006794 | ||
| Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure | Q46094234 | ||
| Pathogenesis of myeloma bone disease | Q46224909 | ||
| Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma | Q46291462 | ||
| Bortezomib or high-dose dexamethasone for relapsed multiple myeloma | Q46549268 | ||
| Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. | Q46573449 | ||
| Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group | Q46859424 | ||
| Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling | Q46868726 | ||
| Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. | Q46907944 | ||
| Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial | Q46985882 | ||
| Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. | Q51401479 | ||
| Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. | Q53127020 | ||
| Prevalence of monoclonal gammopathy of undetermined significance | Q34506801 | ||
| International uniform response criteria for multiple myeloma. | Q34549410 | ||
| Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America | Q34585268 | ||
| Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays | Q34590500 | ||
| Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. | Q34604658 | ||
| Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma | Q34815786 | ||
| International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders | Q34884527 | ||
| Review of 1027 patients with newly diagnosed multiple myeloma | Q35045634 | ||
| Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia | Q35116840 | ||
| Management of multiple myeloma: a systematic review and critical appraisal of published studies | Q35121715 | ||
| Approach to the treatment of multiple myeloma: a clash of philosophies. | Q35230189 | ||
| Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease | Q35794132 | ||
| Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma | Q35848146 | ||
| A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma | Q35848744 | ||
| Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics | Q35849219 | ||
| Proteasome inhibition as a novel therapeutic target in human cancer. | Q36014046 | ||
| Improved survival in multiple myeloma and the impact of novel therapies | Q36478461 | ||
| Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment | Q36480921 | ||
| Myeloma bone disease: pathogenetic mechanisms and clinical assessment. | Q36501851 | ||
| Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition | Q36523517 | ||
| VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma | Q36878944 | ||
| The molecular characterization and clinical management of multiple myeloma in the post-genome era. | Q36939043 | ||
| Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma | Q37038414 | ||
| A monoclonal gammopathy precedes multiple myeloma in most patients | Q37209020 | ||
| Treatment of myeloma: cure vs control | Q37284081 | ||
| Is the International Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant | Q37303841 | ||
| Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines | Q37454445 | ||
| Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma | Q37523265 | ||
| International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). | Q37530452 | ||
| Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens | Q37533983 | ||
| Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis | Q37545358 | ||
| Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma | Q39839596 | ||
| Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma | Q40201943 | ||
| Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma | Q41891711 | ||
| Diagnosis of smoldering multiple myeloma | Q42617275 | ||
| Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p | Q42781523 | ||
| Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial | Q42861085 | ||
| Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. | Q42914716 | ||
| P433 | issue | 3 | |
| P921 | main subject | multiple myeloma | Q467635 |
| P304 | page(s) | 226-235 | |
| P577 | publication date | 2013-03-01 | |
| P1433 | published in | American Journal of Hematology | Q4744246 |
| P1476 | title | Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management | |
| P478 | volume | 88 |
| Q38700339 | A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma |
| Q37709866 | A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications |
| Q28543087 | A novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclasts |
| Q37231523 | Abnormalities in Chromosomes 1q and 13 Independently Correlate With Factors of Poor Prognosis in Multiple Myeloma |
| Q38692424 | Age-related health care disparities in multiple myeloma. |
| Q48666333 | Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis |
| Q87733927 | Can genome array screening replace FISH as a front-line test in multiple myeloma? |
| Q91949934 | Challenges in the cultural adaptation of the German Myeloma Patient Outcome Scale (MyPOS): an outcome measure to support routine symptom assessment in myeloma care |
| Q35097105 | Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma |
| Q34447010 | Clinical course and prognosis of non-secretory multiple myeloma |
| Q34455098 | Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study |
| Q30369423 | Consolidation in multiple myeloma - current status and perspectives |
| Q36325334 | Differential recruitment efficacy of patient-derived amyloidogenic and myeloma light chain proteins by synthetic fibrils-A metric for predicting amyloid propensity |
| Q52638803 | Epidemiology of multiple myeloma in 17 Latin American countries: an update. |
| Q35631433 | Ex Vivo Maintenance of Primary Human Multiple Myeloma Cells through the Optimization of the Osteoblastic Niche |
| Q41031177 | Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation |
| Q26745957 | First line vs delayed transplantation in myeloma: Certainties and controversies |
| Q41914138 | GSK3-mediated MAF phosphorylation in multiple myeloma as a potential therapeutic target |
| Q38115224 | IV. Initial treatment of multiple myeloma. |
| Q61813810 | Immunotherapy in myeloma: how far have we come? |
| Q37171994 | Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma |
| Q33418300 | Improved response rates with bortezomib in relapsed or refractory multiple myeloma: an observational study in Chinese patients |
| Q26777803 | Interpretation of cytogenetic results in multiple myeloma for clinical practice |
| Q38190593 | Is it time for preemptive drug treatment of asymptomatic (smoldering) multiple myeloma? |
| Q37282307 | Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. |
| Q53089985 | MYD88 mutant lymphoplasmacytic lymphoma/Waldenström macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart. |
| Q35766816 | MicroC(3): an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells |
| Q41591687 | Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma |
| Q42086621 | Multiple Myeloma Mimics Bone Metastasis From a Rectal Adenocarcinoma |
| Q38951283 | Multiple myeloma: managing a complex blood cancer |
| Q36318271 | Non-secreting multiple myeloma switches to IgD of lamda type: a case report and review of literature |
| Q47198067 | Outcome and survival of myeloma patients diagnosed 2008-2015. Real world data on 4904 patients from the Swedish Myeloma Registry (SMR). |
| Q40827148 | Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long-term follow-up in a single institution |
| Q36279610 | Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation |
| Q39710073 | Pesticide exposures and the risk of multiple myeloma in men: An analysis of the North American Pooled Project |
| Q33415759 | Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma |
| Q88060350 | Predicting multiple myeloma disease activity by analyzing natural calcium isotopic composition |
| Q40691084 | Prognostic significance of increased bone marrow microcirculation in newly diagnosed multiple myeloma: results of a prospective DCE-MRI study |
| Q38756525 | RGS1 expression is associated with poor prognosis in multiple myeloma |
| Q37325843 | Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels |
| Q37524970 | Risk stratification, treatment selection, and transplant eligibility in multiple myeloma: a qualitative study of the perspectives and self-reported practices of oncologists |
| Q38808490 | Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors. |
| Q36640775 | Small-lymphoid cells and myeloid antigen expression in a patient with IgG myeloma: A case report |
| Q36711842 | Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma |
| Q40813914 | The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea. |
| Q28075927 | The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential |
| Q35996498 | The natural compound forskolin synergizes with dexamethasone to induce cell death in myeloma cells via BIM |
| Q36081225 | The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea |
| Q38211267 | The skinny on obesity and plasma cell myeloma: a review of the literature. |
| Q45728462 | Treatment options for myeloma |
| Q44559311 | Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group |
| Q38255333 | Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back |
| Q35751888 | Well plate-based perfusion culture device for tissue and tumor microenvironment replication |
| Q58023753 | Zielgerichtete Therapien bei hämatologischen Erkrankungen |
Search more.